Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of Concurrent Decitabine in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

NCT02921061 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT02921061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02921061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of Concurrent Decitabine in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
November 17, 2016
Completion date
October 24, 2018
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mixed phenotype acute leukemia, previously treated myelodysplastic syndrome, recurrent adult acute myeloid leukemia, recurrent high risk myelodysplastic syndrome, refractory acute myeloid leukemia, refractory high risk myelodysplastic syndrome, untreated adult acute myeloid leukemia